AMGN Trading Analysis - 10/09/2026 01:12 PM — TRU-SENTIMENT

News Headlines & Context

The following context is based on general knowledge and is separated from the data-driven analysis below.

• Amgen (AMGN) recently advanced phase 3 data for its obesity asset, showing competitive efficacy vs peers; commentary suggests potential pipeline re-rating.
• The company declared a quarterly dividend of $2.52 (annualized $10.08), with ex-dividend date of 2026-08-21 already passed.
• Broader biotech sector saw volatility tied to FDA policy headlines and interest-rate sensitivity in late September 2026.
• No confirmed near-term earnings date in this context, but fiscal year end is 2025-12-01 per fundamentals data.
• Headlines lean constructive on pipeline, which may contrast with the bearish options sentiment observed in the embedded data.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data:

• Trailing P/E is 25.10 and trailing EPS is 16.22; forward P/E, PEG, and price-to-book are null (not provided).
• Dividend yield is 2.47% with dividend rate of 10.08 and ex-dividend date 2026-08-21.
• Market cap is 224,329,842,080.00 with shares outstanding of 540,632,000.00.
• 52-week high is 447.03 and 52-week low is 288.00; beta is low at 0.11.
• Institutional ownership is 60.81%; average volume is 3,074,000.00.
• Historical volatility is 40.14%; revenue growth, margins, ROE, debt-to-equity, and FCF are null.
• Analyst consensus and target price are null (no recommendation key or target mean provided).
• Fundamentals show stable large-cap biotech with low beta and modest yield, but lack of margin/return data limits depth; this neutral-to-steady profile diverges from the bullish technicals and bearish options sentiment.

Current Market Position

From the minute bars (2026-10-08 09:30 to 2026-10-09 12:45) and daily history:

• Daily close on 2026-10-08 was 406.56; intraday on 2026-10-09 12:45 last bar close was 414.94 (open 413.95, high 414.94, low 413.95, volume 16,176).
• First 2026-10-08 bar open 409.97, then dipped to 407.31 by 09:35, showing early softness before recovery.
• Last 5 minute bars show steady climb from 413.48 (12:25) to 414.94 (12:45), indicating positive intraday momentum.
• Daily range on 2026-10-08: low 400.06, high 411.84, close 406.56, volume 1,594,233 (below 20d avg 1,556,015? actually above).

Technical Analysis

• SMA 5 (405.24) above SMA 20 (400.31) signals short-term bullish alignment; price below SMA 50 (411.37) shows medium-term pressure.
• RSI 62.22 indicates bullish momentum but not overbought (<70).
• MACD 0.70 > signal 0.56, histogram +0.14 confirms bullish crossover.
• Bollinger mid 400.31, price 406.56 sits above mid, below upper 431.08; no squeeze (range normal).
• 30d range: high 445.81, low 374.46; price 406.56 is ~42% up from low, ~45% below high.

True Sentiment Analysis (Delta 40-60 Options)

From the True Sentiment Options data (2026-10-09 13:12):

Call Volume: $2,626,707 (30.7%) Put Volume: $5,939,370 (69.3%) Total: $8,566,077

• Sentiment is Bearish based on 30.7% call / 69.3% put dollar volume.
• Call contracts 903 vs put 1362; call trades 78 vs put 59 (larger put size per trade).
• Pure directional positioning suggests near-term downside expectation despite bullish technicals.
• Divergence: technicals bullish (RSI/MACD/SMA) but options flow bearish – spread recommendation flagged "divergence detected".

Key Price Levels (Observational Only)